Major
depressive disorder, also known as the clinical depression, is characterized by a constant
sense of despair and hopelessness. It usually affects daily activities such as
study, sleep, and eating.
Access
Detailed Report Summary:
Common
symptoms observed in major depressive disorder are fatigue, indecisiveness,
impaired concentration, feelings of worthlessness or guilt, insomnia or
hypersomnia, restlessness, significant weight loss or gain and recurring
thoughts of death or suicide.
Request
to Get the Sample Pages at:
According to
the National Institute of Mental Health, an estimated 16.1 million adults aged
18 or older in the U.S. had at least one major depressive episode in 2014.
VistaGen Therapeutics
Inc. is developing AV-101, a new generation oral antidepressant, for the
treatment of major depressive disorder. NeurOp Inc., and ACADIA Pharmaceuticals
Inc. are some other key players involved in the development of drugs for the
treatment of major depressive disorder.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
